Literature DB >> 7705931

Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids.

J Pongracz1, P Clark, J P Neoptolemos, J M Lord.   

Abstract

Expression of protein kinase C (PKC) isoenzymes was determined in paired samples of normal mucosa and colorectal cancer tissue from 13 patients. Total PKC activity in cancer tissue was significantly decreased compared to that in normal mucosa. Western blotting, using PKC isoenzyme-specific antibodies, showed that two PKC isoenzymes, PKC beta and PKC epsilon, were significantly decreased in cancer tissue. The level of PKC delta was increased in cancer tissue and the expression of PKC alpha and zeta was not altered significantly. Primary bile acids--cholic acid (CA) and chenodeoxycholic acid (CDCA)--and the principal secondary bile acids--deoxycholic acid (DCA), lithocholic acid (LCA) and ursodeoxycholic acid (UDCA)--were found to be potent and selective activators of partially purified PKC isoenzymes. PKC beta 1 was the isoenzyme most effectively activated by secondary bile acids. Our data provide a model for the involvement of secondary bile acids in colorectal carcinogenesis through specific PKC isoenzyme modulation in colorectal mucosa.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705931     DOI: 10.1002/ijc.2910610107

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  37 in total

Review 1.  Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states.

Authors:  Amani Batarseh; Vassilios Papadopoulos
Journal:  Mol Cell Endocrinol       Date:  2010-06-30       Impact factor: 4.102

Review 2.  Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis.

Authors:  E M Deacon; J Pongracz; G Griffiths; J M Lord
Journal:  Mol Pathol       Date:  1997-06

Review 3.  Protein kinase C as a tumor suppressor.

Authors:  Alexandra C Newton
Journal:  Semin Cancer Biol       Date:  2017-05-02       Impact factor: 15.707

4.  NF-kappaB regulates intestinal epithelial cell and bile salt-induced migration after injury.

Authors:  Eric D Strauch; Barbara L Bass; Jaladanki N Rao; Jennifer A Vann; Jian-Ying Wang
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

Review 5.  Posttranslational control of HuR function.

Authors:  Ioannis Grammatikakis; Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-06-16       Impact factor: 9.957

6.  Histone hyperacetylation up-regulates protein kinase Cδ in dopaminergic neurons to induce cell death: relevance to epigenetic mechanisms of neurodegeneration in Parkinson disease.

Authors:  Huajun Jin; Arthi Kanthasamy; Dilshan S Harischandra; Naveen Kondru; Anamitra Ghosh; Nikhil Panicker; Vellareddy Anantharam; Ajay Rana; Anumantha G Kanthasamy
Journal:  J Biol Chem       Date:  2014-10-23       Impact factor: 5.157

7.  PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1.

Authors:  Marybeth A Pysz; Olga V Leontieva; Nicholas W Bateman; Joshua M Uronis; Kathryn J Curry; David W Threadgill; Klaus-Peter Janssen; Sylvie Robine; Anna Velcich; Leonard H Augenlicht; Adrian R Black; Jennifer D Black
Journal:  Exp Cell Res       Date:  2009-02-14       Impact factor: 3.905

8.  Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.

Authors:  Yanqiao Zhang
Journal:  Drugs Future       Date:  2010-08-01       Impact factor: 0.148

9.  Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer.

Authors:  B L Allen-Petersen; C J Carter; A M Ohm; M E Reyland
Journal:  Oncogene       Date:  2013-03-11       Impact factor: 9.867

10.  Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

Authors:  K A Benhadji; M Serova; A Ghoul; E Cvitkovic; C Le Tourneau; S M Ogbourne; F Lokiec; F Calvo; P Hammel; S Faivre; E Raymond
Journal:  Br J Cancer       Date:  2008-12-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.